Établissement français du sang, Bretagne, Rennes
Blood transfusion has been, historically, the first replacement therapy using human products. Despite forty years of research on oxygen carriers, no alternative is available and will not be very likely in the next ten years. However, supply for blood cellular components and plasma-derived products have increased for several years, probably because of increasing life expectancy. Managed by the “Etablissement Français du Sang”, sole operator authorized to collect blood components in the French civilian population, whole blood and apheresis donations are based on ethical values that protect donors and recipients. This organization is framed by a device regulatory and inspections conducted by the “Agence Française de Sécurité Sanitaire des Produits de Santé/” (French Agency of Sanitary Safety of Health Products).